Ikarian Capital LLC Grows Stake in Immunic, Inc. (NASDAQ:IMUX)

Ikarian Capital LLC boosted its stake in shares of Immunic, Inc. (NASDAQ:IMUX) by 258.3% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,612,378 shares of the company’s stock after purchasing an additional 1,162,378 shares during the period. Ikarian Capital LLC owned about 1.79% of Immunic worth $2,128,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Gratus Capital LLC increased its holdings in shares of Immunic by 15.1% in the fourth quarter. Gratus Capital LLC now owns 1,941,454 shares of the company’s stock worth $2,912,000 after purchasing an additional 254,999 shares during the last quarter. Sierra Summit Advisors LLC purchased a new stake in shares of Immunic in the fourth quarter valued at approximately $487,000. Summit Trail Advisors LLC purchased a new stake in shares of Immunic in the first quarter valued at approximately $25,000. Vanguard Group Inc. boosted its holdings in shares of Immunic by 100.7% in the first quarter. Vanguard Group Inc. now owns 3,394,047 shares of the company’s stock valued at $4,480,000 after purchasing an additional 1,703,047 shares during the period. Finally, BVF Inc. IL purchased a new stake in shares of Immunic in the first quarter valued at approximately $11,752,000. 51.82% of the stock is currently owned by hedge funds and other institutional investors.

Immunic Stock Performance

Shares of NASDAQ IMUX traded down $0.03 during mid-day trading on Thursday, hitting $1.40. The stock had a trading volume of 155,387 shares, compared to its average volume of 584,839. The company has a 50 day moving average of $1.25 and a two-hundred day moving average of $1.27. Immunic, Inc. has a twelve month low of $0.95 and a twelve month high of $2.39. The firm has a market cap of $126.11 million, a PE ratio of -0.77 and a beta of 1.77.

Immunic (NASDAQ:IMUX) last announced its quarterly earnings results on Wednesday, May 8th. The company reported ($0.25) earnings per share for the quarter, topping the consensus estimate of ($0.27) by $0.02. Equities research analysts predict that Immunic, Inc. will post -0.94 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities analysts recently commented on the stock. StockNews.com downgraded shares of Immunic from a “hold” rating to a “sell” rating in a research note on Thursday, July 25th. Brookline Capital Management reissued a “buy” rating and issued a $10.00 price objective on shares of Immunic in a research note on Friday, April 5th. Finally, Piper Sandler reissued an “overweight” rating and issued a $28.00 price objective on shares of Immunic in a research note on Tuesday, July 16th.

About Immunic

Immunic, Inc, a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis.